01

On July 12, 2023, the 4th installment of the Global Frontiers in Biomedical Technology Conference kicked off with great fanfare at the Suzhou International Expo Center, located by the scenic Jinji Lake. Among the notable attendees was RocRock Biotech, a significant entity in the field. Dr. Yin Xiushan, the CEO of RocRock Biotech, delivered an in-depth presentation on the company's recent progress and breakthroughs in CAR-M treatments for solid tumors, which piqued the interest and ignited extensive conversations among the experts and attendees present.

02

 This edition of the conference, under the theme "Channeling Frontier Technologies to Stimulate Innovation in China's Pharmaceutical Sector," zeroes in on the latest biomedical advancements. It addresses key areas including drug regulation, pioneering tech, innovation, commercialization, and talent development. The gathering convenes a prestigious group of international scientists, CEOs of pharmaceutical firms, and investment leaders to engage in progressive discussions and exchanges.

、

(Dr. Yin Xiushan, CEO of RocRock Biology）

03

 In the focus on the advancement of cellular medicine, Dr. Yin Xiushan commenced the presentation by sharing the founding story of RocRock Biotech and his personal venture journey. Within a short span of two years,RocRock Biotech has made significant breakthroughs in CAR-M therapies for solid tumors, rapidly advancing in biopharmaceutical research. Dr. Yin then elaborated on the evolution of macrophage therapy in treating solid tumors, and with robust scientific data and experimental confirmation, he underscored the necessity and vast potential of macrophage therapy in this domain.

04

2. Dr. Yin Xiushan elaborated on RocRock Biotech's proprietary suite of four cutting-edge core technology platforms in his presentation, which include the Macrophage-Specific CAR Design Platform, the Macrophage Optimization Culture Platform, the Rapid Infection and Culture Platform for Mononuclear Cells, and the Macrophage-Specific Viral Modification Platform. These platforms address the previously weak anti-cancer capabilities of resting macrophages, the challenges in culturing and expanding macrophages outside the body, the lengthy culture periods and high costs associated with ex vivo macrophage culture, and the difficulties in genetically modifying macrophages. The successful implementation of these platforms has laid a robust groundwork for the research and development of CAR-M therapies.

05

In his presentation, Dr. Yin Xiushan elaborated on RocRock Biotech's distinct suite of four core technology platforms: the Macrophage-Specific CAR Design Platform, the Macrophage Optimization Culture Platform, the Rapid Infection and Culture Platform for Mononuclear Cells, and the Macrophage-Specific Viral Modification Platform. These platforms address the previously weak anti-cancer capabilities of resting macrophages, the challenges in culturing and expanding macrophages outside the body, the lengthy culture periods and high costs associated with ex vivo macrophage culture, and the difficulties in genetically modifying macrophages. The successful deployment of these platforms has laid a robust groundwork for the research and development of CAR-M therapies.